Skip to main content

Advertisement

Table 3 Chemotherapy, antiemetic prophylaxis and CINV outcomes

From: Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study

  Breast cancer Carboplatin-treated lung cancer Cisplatin-treated lung cancer
  All Older 5-HT3RAs Palonosetron P* All Older 5-HT3RAs Palonosetron P All Older 5-HT3RAs Palonosetron P
N 3,606 1,742 186   4,497 2,691 1,806   1,154 764 390  
CT tx days, mean (SD) 4.2 (1.2) 4.3 (1.3) 4.2 (1.2) 0.0297 6.1 (3.7) 6.2 (3.6) 6.1 (3.6) NS 5.8 (4.3) 6.3 (4.7) 4.9 (3.2) <0.0001
All antiemetic claims 9.1 (5.1) 9.9 (5.5) 8.3 (4.6) <0.0001 10.2 (6.7) 11.4 (7.2) 8.5 (5.4) <0.0001 13.0 (8.0) 15.3 (8.0) 8.5 (5.6) <0.0001
All 5-HT3 RA claims 7.0 (3.9) 7.9 (4.2) 6.2 (3.4) <0.0001 9.2 (6.0) 10.3 (6.4) 7.7 (4.9) <0.0001 10.9 (6.9) 13.1 (6.8) 6.4 (4.4) <0.0001
Days with hospital/ED associated CINV events 0.1 (0.7) 0.1 (0.9) 0.1 (0.4) 0.0052 0.3 (1.3) 0.3 (1.4) 0.2 (1.2) 0.0004 0.6 (2.0) 0.7 (2.1) 0.6 (1.9) 0.0499
Pts with > =1 hospital/ED associated CINV events, N (%) 161 (4.5) 95 (5.5) 66 (3.5) 0.0055 516 (11.5) 345 (12.8) 171 (9.5) 0.0005 230 (19.9) 166 (21.7) 64 (16.4) 0.0324
  1. CT: chemotherapy, Tx: treatment, ED: emergency department, pts: patients.
  2. P values were based on t-tests, except for days and proportions of patients with hospital/ED associated CINV events, where the nonparametric Wilcoxon and Chi-square tests were used, respectively.